AptarGroup (ATR) Q4 2024 earnings summary

Executive summary

• Achieved 3% reported and core sales growth in 2024, reaching $3.6B in annual sales, with Q4 core sales up 2% and adjusted EPS of $1.52, exceeding guidance due to strong operational performance and a lower tax rate.

• Net income rose 32% to $375M for the year, with Q4 net income up 62% to $101M, driven by pharma solutions growth, strong closures demand, and productivity gains.

• Double-digit EPS growth and margin expansion achieved for the second consecutive year, led by pharma and closures segments.

• 2024 marked the 31st consecutive year of increasing annual dividends.

• Productivity gains, cost reductions, and innovation supported margin expansion across all segments.

Financial highlights

• Q4 2024 reported sales: $848M (+1% year-over-year); adjusted EBITDA: $195M (+9%), margin at 23%.

• Q4 adjusted EPS was $1.52 (up 27%); diluted EPS was $1.49 (up 60%).

• Full-year 2024 reported sales: $3.58B (+3%); adjusted EPS: $5.64 (+18%); adjusted EBITDA: $775M (21.6% margin).

• Net cash from operations increased 12% to $643M; free cash flow up 40% to $367M.

• Q4 effective tax rate was 13% (down from 23%); full-year effective tax rate at 20%.

Outlook and guidance

• Q1 2025 adjusted EPS expected in the range of $1.11–$1.19, with a 7% currency headwind and higher tax rate (25–27%).

• 2025 is expected to deliver solid earnings growth, led by pharma, despite significant negative impacts from currency and tax.

• Anticipate capital expenditures of $280–$300M in 2025, mostly allocated to pharma.

• Softer Q1 demand expected in prestige fragrance, skincare, and nasal decongestants; gradual improvement anticipated through the year.

• Anticipates about a 15% combined impact from currency and tax in Q1.